Weiss Ratings Reiterates Sell (E+) Rating for Treace Medical Concepts (NASDAQ:TMCI)

Key Points

• Weiss Ratings has reissued a "sell (E+)" rating for Treace Medical Concepts (NASDAQ: TMCI), signaling caution for investors regarding the stock's performance.
• Analysts have mixed opinions on TMCI, with price objectives ranging from a low of $6.00 to a high of $8.00, indicating uncertainty about its market prospects.
• Despite recent trading up 2.7% to $6.16, Treace Medical Concepts reported a negative EPS of ($0.28), and analysts expect continued losses with a forecasted EPS of -0.92 for the current fiscal year.

Treace Medical Concepts (NASDAQ:TMCI - Get Free Report)'s stock had its "sell (e+)" rating reissued by research analysts at Weiss Ratings in a research report issued to clients and investors on Wednesday,Weiss Ratings reports.

A number of other equities analysts also recently commented on the company. Stifel Nicolaus reduced their price objective on Treace Medical Concepts from $9.00 to $6.00 and set a "hold" rating on the stock in a research report on Friday, August 8th. UBS Group reaffirmed a "neutral" rating and issued a $6.50 price objective (down from $8.60) on shares of Treace Medical Concepts in a research note on Friday, August 8th. Finally, Truist Financial lifted their price objective on Treace Medical Concepts from $6.60 to $8.00 and gave the company a "hold" rating in a research note on Thursday, September 4th. Two analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus target price of $9.83.

Treace Medical Concepts Trading Up 2.7%

Treace Medical Concepts stock traded up $0.16 during trading on Wednesday, reaching $6.16. 172,090 shares of the company were exchanged, compared to its average volume of 307,501. Treace Medical Concepts has a 52-week low of $4.54 and a 52-week high of $10.79. The company has a market capitalization of $389.13 million, a P/E ratio of -7.80 and a beta of 0.69. The company has a debt-to-equity ratio of 0.55, a current ratio of 3.52 and a quick ratio of 2.51. The stock's 50 day simple moving average is $6.77 and its two-hundred day simple moving average is $6.59.

Treace Medical Concepts (NASDAQ:TMCI - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported ($0.28) EPS for the quarter, topping analysts' consensus estimates of ($0.29) by $0.01. Treace Medical Concepts had a negative return on equity of 46.76% and a negative net margin of 23.01%.The firm had revenue of $47.39 million for the quarter, compared to the consensus estimate of $47.08 million. Treace Medical Concepts has set its FY 2025 guidance at EPS. On average, equities research analysts expect that Treace Medical Concepts will post -0.92 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in TMCI. Invesco Ltd. increased its position in shares of Treace Medical Concepts by 18.6% during the second quarter. Invesco Ltd. now owns 15,051 shares of the company's stock worth $88,000 after acquiring an additional 2,362 shares during the last quarter. Wealth Enhancement Advisory Services LLC lifted its position in Treace Medical Concepts by 1.1% in the first quarter. Wealth Enhancement Advisory Services LLC now owns 244,800 shares of the company's stock worth $2,054,000 after purchasing an additional 2,645 shares during the period. Palumbo Wealth Management LLC lifted its position in Treace Medical Concepts by 15.4% in the first quarter. Palumbo Wealth Management LLC now owns 25,690 shares of the company's stock worth $216,000 after purchasing an additional 3,431 shares during the period. Birchview Capital LP lifted its position in Treace Medical Concepts by 2.2% in the first quarter. Birchview Capital LP now owns 164,947 shares of the company's stock worth $1,384,000 after purchasing an additional 3,597 shares during the period. Finally, Osaic Holdings Inc. lifted its holdings in shares of Treace Medical Concepts by 328.3% during the second quarter. Osaic Holdings Inc. now owns 4,793 shares of the company's stock valued at $28,000 after purchasing an additional 3,674 shares during the last quarter. Institutional investors and hedge funds own 84.08% of the company's stock.

Treace Medical Concepts Company Profile

Treace Medical Concepts, Inc, a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty 3D bunion correction system that combines instruments, implants, and surgical methods designed to surgically correct three planes of the bunion deformity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.